Monash University and oNKo-innate announce research partnership
An innovative research partnership has been established between Monash University and new Melbourne-based start-up, oNKo-innate Pty Ltd.
The unique partnership sees oNKo-innate, co-founded by Professor Nicholas Huntington and Dr Jai Rautela, being based at the Monash Biomedicine Discovery Institute (BDI). The partnership strengthens immunology and cancer research at the BDI, with oNKo-innate developing novel approaches to immunotherapy using the expertise in Natural Killer (NK) cell biology.
This new model of partnership demonstrates Monash BDI's vision of fostering an innovation-led research environment where discovery researchers are encouraged to partner with industry and establish their own start-ups.
The Monash BDI’s industry-based research revenue has grown significantly and is now home to multiple young biotech start-ups and spin outs.
Professor John Carroll, Director of Monash BDI, said the arrival of the oNKo-innate team, who recently announced a major multi-year partnership with Gilead, exemplifies this approach.
“This is a great example of discovery research moving rapidly to a major industry partnership in order to accelerate the development of new cancer therapies. The partnership is improving health and creating new jobs at the interface of research and commercial development for some of Australia’s best young scientists,” Professor Carroll said.
For more details, read the full Monash University media release.
About the Monash Biomedicine Discovery Institute at Monash University
Committed to making the discoveries that will relieve the future burden of disease, the newly established Monash Biomedicine Discovery Institute at Monash University brings together more than 120 internationally-renowned research teams. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.
oNKo-innate is a discovery-stage biotechnology company dedicated to target identification and pre-clinical immuno-oncology drug development. With our deep understanding of NK cells, we aim to be the first to truly therapeutically harness the cancer-fighting abilities of these remarkable white blood cells. For more information on oNKo-innate, visit www.onko-innate.com